Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Fulminant viral hepatitis is a severe liver disease with high mortality.
• Hepatitis B virus (HBV), hepatitis D virus (HDV), and hepatitis A virus (HAV) can cause acute liver failure.
• Interferons are cytokines with antiviral properties, but their efficacy in severe hepatitis is debated.

Purpose of the Study:

• To evaluate the therapeutic efficacy of recombinant alpha 2c-interferon in patients with fulminant viral hepatitis.
• To assess the impact of interferon therapy on survival and disease progression in different viral hepatitis etiologies.

Main Methods:

• A cohort of 12 consecutive patients with fulminant viral hepatitis received recombinant alpha 2c-interferon.
• Patients had various causative agents including HBV, HDV, and HAV coinfections or superinfections.
• Interferon therapy was initiated upon presentation with hepatic encephalopathy, excluding grade IV coma patients.

Main Results:

• Ten out of twelve patients (83%) died during the study period.
• Only two patients survived, one of whom developed chronic delta infection and liver cirrhosis despite 3 months of interferon treatment.
• No significant therapeutic benefit was observed, particularly in cases involving HDV.

Conclusions:

• Recombinant alpha 2c-interferon demonstrates limited therapeutic value in treating fulminant viral hepatitis.
• The presence of HDV appears to significantly reduce the potential efficacy of alpha 2c-interferon therapy.
• Further research is needed to explore alternative treatments for severe viral hepatitis, especially HDV-related cases.